Dépêches

Sparton Medical Recognized for Teaming with BioMarker Strategies and HS Design to Automate Live Tumor-Cell Processing

Dépèche transmise le 1 mai 2012 par Business Wire

STRONGSVILLE, Ohio--(BUSINESS WIRE)--Sparton Corporation (NYSE:SPA) announces that Sparton Medical’s collaborative design and engineering work with HS Design in Gladstone, NJ has helped BioMarker Strategies become a finalist for a 2012 Medical Design Excellence Award (MDEA).

“It is an honor to be named a finalist”

BioMarker Strategies, located in Baltimore, MD, recently announced that its SnapPath™ 1000 testing platform was named a finalist in the In vitro diagnostics category in the MDEA competition. The instrument, developed with funding support from the National Cancer Institute and manufactured by Sparton Medical, is an automated live-tumor-cell processing device that enables next-generation biomarker tests, known as Functional Signaling Profiles (FSPs), to guide targeted drug therapy selection.

“We congratulate BioMarker Strategies on being named a finalist for this prestigious award, and we’re proud to have been a partner in developing this leading-edge platform that integrates custom disposables with custom equipment,” said Cary Wood, president and CEO of Sparton Corp. “Our Sparton Medical team is also pleased to have been recognized as a partner to a Medical Design Excellence Award finalist for the third time in the last four years.”

The Medical Design Excellence Awards (www.MDEAwards.com) are the medical device industry’s premier design awards competition. It is the only awards program that exclusively recognizes contributions and advances in the design of medical products. Entries are evaluated on the basis of design and engineering features, including innovative use of materials and user-related functions that improve healthcare delivery and change traditional medical attitudes or practices. Judges also consider features that provide enhanced benefits to the patient, and the ability of the product development team to overcome design and engineering challenges so that the product meets its clinical objectives.

“It is an honor to be named a finalist,” remarked Adam Schayowitz PhD, MBA, Sr. Director of Operations and Business Development for BioMarker Strategies. “Our partnership with Sparton and HS Design was instrumental in bringing the SnapPath™ technology to life. Both companies brought depth, professionalism, and creative problem-solving to the table—enabling us to meet important milestones on time and on budget.”

The MDEA winners will be announced on May 23, 2012, at a cocktail reception being held in conjunction with the MD&M East event, May 22-24, at the Pennsylvania Convention Center in Philadelphia.

It was at the MD&M Show in 2009 when long-time partners HS Design and Sparton Medical were introduced to BioMarker Strategies. Since then, the team has worked to develop and launch a first-of-kind live cancer cell diagnostic instrument.

“These relationships and this platform extend Sparton Medical’s commitment and history of developing progressive instruments that serve the IVD market,” said Michael Gaul, General Manager of Sparton Medical.

About BioMarker Strategies

BioMarker Strategies is developing the SnapPath™ live tumor cell testing system to enable next-generation biomarker tests for solid-tumor based cancers, including advanced melanoma. The SnapPath™ system incorporates an automated, live-tumor-cell processing device with first-in-class, functional, ex vivo biomarker tests to inform clinical decision making for targeted cancer therapeutics. SnapPath™ stimulates a patient’s live tumor cells outside their body to obtain a Functional Signaling Profile (FSP™) of the signal transduction network that is not possible using static, genomic biomarkers from dead, fixed tissue. The company is located at the Johns Hopkins Science + Technology Park in East Baltimore. The development of the SnapPath™ system is supported with significant funding from the National Cancer Institute. For more information about BioMarker Strategies, please refer to www.biomarkerstrategies.com.

About HS Design

HS Design Inc., located in Gladstone, NJ, is a full-service product development firm focusing on user-driven design for the medical and Life Science industry. The firm is a recognized leader in the field, producing more than 400 successful products since its inception 40 years ago. HSD partners with a wide range of companies, from Fortune 100 firms to start-up ventures, to develop a variety of market-leading surgical tools, diagnostic instruments and consumer healthcare products. Services include contextual research, market strategy, industrial design, packaging, mechanical engineering, FEA simulation, rapid prototyping, V&V and manufacturing liaison. For more information regarding HSD, please visit www.hs-design.com.

About Sparton Medical

Sparton Medical is a division of Sparton Corporation (NYSE: SPA), whose operations are comprised of contract development, design, production and fulfillment of complex and sophisticated medical class I, class II, and class III devices in its FDA registered and ISO 13485 certified facilities. We assure product reliability and safety in accordance with Food and Drug Administration (“FDA”) guidelines and GMP manufacturing procedures for each product we design and manufacture. Sparton Medical specializes in systems and procedures that meet the requirements of medical OEM and emerging technology customers in the In Vitro Diagnostic Therapeutic and Surgical Devices market segments. For more information, visit www.sparton.com/medical.

Some of the information in this release contains our projections or other forward-looking statements regarding future events. We wish to caution you that these statements are only predictions and actual events or results may differ materially. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors. Forward-looking statements included herein are made as of the date hereof, and we undertake no obligation to update publicly such statements to reflect subsequent events or circumstances. Actual results could differ materially from anticipated results.